Australia markets open in 26 minutes
  • ALL ORDS

    7,278.60
    +19.10 (+0.26%)
     
  • AUD/USD

    0.6961
    -0.0006 (-0.09%)
     
  • ASX 200

    7,029.80
    +9.20 (+0.13%)
     
  • OIL

    90.57
    +0.07 (+0.08%)
     
  • GOLD

    1,810.20
    -2.10 (-0.12%)
     
  • BTC-AUD

    33,352.99
    -1,065.10 (-3.09%)
     
  • CMC Crypto 200

    537.23
    -20.12 (-3.61%)
     

Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., May 17, 2022--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the upcoming H.C. Wainwright Global Investment Conference May 23-25, 2022.

H.C. Wainwright Global Investment Conference Presentation (hybrid)
Date:
Tuesday, May 24th, 2022
Time: 7:00 am Eastern Standard Time
Speaker: Adelene Perkins, Chief Executive Officer
Format: Company presentation and virtual 1-on-1 meetings
Webcast Registration Link.
*a replay will be available following the presentation for 90 days

About Infinity and Eganelisib
Infinity Pharmaceuticals, Inc. ("Infinity" or the "Company"), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic in multiple clinical studies. MARIO-4 is a frontline mTNBC randomized, double-blind, pivotal trial the Company expects to initiate by the end of 2022. MARIO-3 is the first eganelisib combination study in frontline advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in frontline TNBC and in combination with Tecentriq and Avastin® in frontline RCC. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo® (nivolumab) in I/O naïve urothelial cancer. MARIO-P is a clinical program to evaluate eganelisib across various solid tumor indications, which the Company expects to initiate on a rolling basis in 3Q 2022. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Opdivo® is a registered trademark of Bristol Myers Squibb.
Tecentriq® is a registered trademark of Genentech, Inc.
Abraxane® is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company.
Avastin® is a registered trademark of Genentech, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005155/en/

Contacts

Irina Koffler
LifeSci Advisors, LLC
646-970-4681
ikoffler@lifesciadvisors.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting